Related Experiment Video
Updated: May 5, 2026
11:49
The Corneal Micropocket Assay: A Model of Angiogenesis in the Mouse Eye
Published on: August 16, 2014
16.7K
VEGFR3 pathway in corneal transplantation
Mariateresa Laborante1,2, Alessandra Micera3, Daniele Gaudenzi1,2
1Ophthalmology Campus Bio-Medico University, Rome, Italy.
Acta Ophthalmologica
|February 6, 2025
Summary
High-risk corneal transplants show elevated vascular endothelial growth factor receptor 3 (VEGFR3) linked to inflammation and rejection. Targeting the VEGF-C/D-VEGFR3 pathway may improve graft survival in these challenging cases.
Area of Science:
- Ophthalmology
- Immunology
- Molecular Biology
Background:
- Corneal transplantation is common but high-risk cases face graft rejection due to inflammation and host bed vascularization.
- Current treatments struggle to prevent rejection in high-risk corneal grafts.
Purpose of the Study:
- Investigate the role of the vascular endothelial-derived growth factor (VEGF)-C/D-VEGFR3 pathway in corneal transplantation.
- Determine the pathway's impact on inflammation and immune response in high-risk corneal grafts.
Main Methods:
- Evaluated 42 patients undergoing corneal transplantation with clinical assessments and molecular analyses.
- Measured VEGFR3, VEGF-C, VEGF-D, VEGF-A, and inflammatory markers (ICAM-1, HLA-DR) post-transplantation.
Main Results:
- VEGF-C/D and VEGFR3 expression differed between high-risk (HR) and low-risk (LR) transplants.
- Elevated VEGFR3 in HR cases correlated with increased inflammation (ICAM-1, HLA-DR) and higher graft rejection risk.
Conclusions:
- The VEGF-C/D-VEGFR3 pathway is crucial in modulating immune responses and inflammation in corneal transplantation, especially in HR cases.
- Targeting this pathway offers potential therapeutic strategies to reduce inflammation and enhance graft survival.
- Further research is needed to validate these findings and explore therapeutic applications for improved transplant outcomes.
